Searching journal content for articles similar to Geisler and Renquist 234 (1): R1.

Displaying results 1-10 of 38
For checked items
  1. .../EBPα and peroxisome proliferator–activated receptor (PPAR) γ (Cook & Cowan 2008, Berry  et  al. 2014, Lim  et  al. 2015). Recently, it has also been shown that hyperinsulinemia promotes adipose tissue inflammation in mice, which contributes to disruption of metabolic processes such as de novo lipogenesis in WAT...
  2. ...& Maratos-Flier E 2010 Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139 456–463. (doi:10.1053/j.gastro.2010.04.054) Published by Bioscientifica Ltd. Research J P G CAMPOREZ and others Mice lacking Fgf21 are hepatic insulin-resistant 226 :3 216...
  3. ...can result in hypoglycemia, muscle atrophy, or ketoacidosis, whereas overconsumption, in addition to causing weight gain and/or obesity if chronically overconsumed, can lead to disruptions in sleep-wake cycles, increased risk for nonalcoholic fatty liver disease (NAFLD) and insulin resistance (Flowers...
  4. ...reported in females of many mammalian species, which may also corroborate a protective role of estrogen (Borrás  et  al. 2003, 2010, Viña et al. 2005). All in all, estrogen seems to positively influence mitochondrial function and energy homeostasis. The peroxisome proliferator-activated receptor gamma...
  5. ..., University of Illinois at Chicago, Chicago, Illinois, USA 3Biologic Resources Laboratory, University of Illinois at Chicago, Chicago, Illinois, USA *(A Wolf Greenstein and N Majumdar contributed equally to this work) Abstract Peroxisome proliferator-activated receptor γ (PPARγ) is the target...
  6. ..., and others. Most of Th cells express CD4 and can be further categorized accordingactivation state. Published by Bioscientifica Ltd. their density correlated positively with the incidence of Th17 cells Review M MRAZ and M HALUZIK Role of immune cells in obesity 222 :3 R121nonalcoholic fatty liver disease...
  7. ...of diabetes (Secchiero et  al. 2013). Similarly, targeting the peroxisome proliferator-activated receptor-γ (PPARγ) has been a proven strategy for the drug development against obesity and diabetes (Blaschke et  al. 2006). PPARγ forms a heterodimer with retinoid X receptor (RXR), and PPARγ/RXR complexes can...
  8. ...diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. Journal of Clinical Endocrinology and Metabolism 89 463–478. (doi:10.1210/jc.2003-030723) Bruun JM, Lihn AS, Pedersen SB & Richelsen B 2005 Monocyte chemoattractant protein-1 release is higher...
  9. ...); Adip, adiponectin; Avy/a, viable yellow agouti; Cebpa, CCAAT/enhancer-binding protein-alpha; HFD, high-fat diet; IU, in utero; Lep, leptin; LFD, low-fat diet; Pparg, peroxisome proliferator-activated receptor gamma; OG, offspring group (genetic background × postnatal environment); VDD, vitamin D...
  10. ...). In addition, circulating aP2 has also been linked to carotid atherosclerosis in humans (Yeung et al. 2007) and nonalcoholic fatty liver disease (NAFLD; Koh et al. 2009). In NAFLD patients, elevated plasma aP2 levels independently http://.endocrinology-journals.org DOI: 10.1530/JOE-13-0339 2014 Society...
For checked items